MigreLief+M Travel Size

Effective Nutritional Support for Women Experiencing Menstrual, PMS, Menopausal, and Hormonal Fluctuations Contributing to Migraines

MigreLief+M is an effective combination of 8 key ingredients in one formula. Ingredients shown in human clinical studies to balance already normal blood sugar levels and hormones when women are most susceptible to migraines—during monthly menstruation, the reproductive years, and during perimenopause and menopause.*

MigreLief+M provides effective support to women with the following hormone related symptoms:

• Neurological discomfort
• Breast tenderness
• Cravings
• Bloating
• Low mood
• Irritability
• Difficulty focusing
• Weight gain
• Irregular menstrual cycles

Recommended by headache specialists and healthcare professionals.

Learn More in our Health Library

*This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. 

MigreLief+M is intended for use by menstruating females, or pre-menopausal/menopausal women who suffer from chronic migraines associated with their periods or menopause and/or symptoms of PMS and symptoms of PCOS.

Take one caplet twice a day for 90 days during the build-up period. To maintain benefits, continue daily use. For as-needed additional support and comfort, try adding MigreLief-NOW following recommended use directions for that product.

Caution: Not recommended for use during pregnancy, during lactation, or for young females prior to menstruation.

Please note:

• Riboflavin (Vitamin B-2) can cause urine to become bright yellow. This is normal and harmless.
• Although rare, some individuals experience transient (short term) diarrhea when taking magnesium.
• Like most dietary supplements, use of MigreLief+M should be discontinued one week before any surgery.

1. Brown D, Gaby A, Reichert R. Clinical Applications of Natural Medicine–Migraine. NPRC Condition-Specific Monograph Series, 1997.
2. Lawrence Review of Natural Products, September 1994.
3. Awang DVC. Herbal Medicine, Feverfew. Canadian Pharm J 1989; 122:266-70.
4. Heptinstall S, Awang DVC, Dawson BA, et al. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol 1992; 44:391-5.
5. Pugh WJ, Sambo K. Prostaglandin Synthetase Inhibitors in Feverfew. J Pharm Pharmacol 1988; 40-743-5.
6. Heptinstall S, White A, Williamson L, Mitchell JRA. Extracts of Feverfew Inhibit Granule Secretion in Blood Platelets and Polymophonuclear Leukocytes. Lancet 1985; i:1071-4.
7. Makheja AN, Bailey JM. A Platelet Phospholipase Inhibitor from the Medicinal Herb Feverfew (Tanacetum parthenium). Prostagland Leukotrienes Med 1982;8:653-60.
8. Sumner H, Salan U, Knight DW, Hoult JRS. Inhibition of 5-Lipoxygenase and Cyclo-oxygenase in Leukocytes by Feverfew. Biochem Pharmacol 1992;43:2313-20.
9. Johnson ES, Kadam NP, Hylands DM, Hylands PF. Efficacy of Feverfew As prophylactic Treatment of Migraine. British Med J 1985; 291:569-73.
10. Murphy JJ. Heptinstall S, Mitchell JRA. Randomized Double-Blind Placebo-Controlled Trial of Feverfew in Migraine Prevention. Lancet 1988; ii:189-92.
11. Altura BM. Calcium Antagonist Properties of Magnesium: Implications for Anti-migraine Actions. Magnesium 1985; 4:169-75.
12. Ramadan NM, Halvorson H, Vande-Linde A, et al. Low Brain Magnesium in Migraine. Headache 1989; 29:590-93.
13. Weaver K. Magnesium and Migraine. Headache 1990; 30:168.
14. Faccinetti F, Sances G, Borella P, et al. Magnesium Prophylaxis of Menstrual Migraine: Effects on Intra-cellular Magnesium. Headache 1991; 31:298-304.
15. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of Migraine with Oral Magnesium: Results from a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study. Cephalalgia 1996; 16:257-63.
16. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the Prophylaxis of Migraine–A Double-Blind, Placebo-Controlled Study. Cephalalgia 1996;16:436-40.
17. Schoenen J, Lenaerts M, Bastings E. High-dose Riboflavin as a Prophylactic Treatment of Migraine: Results of an Open Pilot Study. Cephalalgia 1994l14:328-9
18. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomised controlled trial. Neurology 1998; 50: 46670.
19. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004 Jul;11(7):475-7.
20. Maria Condò1, Annio Posar1, Annalisa Arbizzani1 and Antonia Parmeggiani1 Riboflavin prophylaxis in pediatric and adolescent migraine. The Journal of Headache and Pain: Volume 10, Number 5 / October, 2009
21. Schellenberg R. Treatment for PMS with agnus castus. BMJ. 2001 Han 20;322(7279):134-7
22. Haut-und Gesch. 1964; 36:220 Giss, G. Rothenburg,W.
23. Ggw 1967;106:124-6 Amann W. Improvement of acne vulgaris with Agnus castus
24. Zbl GynSkol 1959 81:701 Bleier, W.
25. Medica Emperica 1990, 9”494-502 Bohnert, K.J. Hahs, G. Phytotherapy in Gynecology and Obstetrics (Chasteberry) Acta
26. clin. Biochem Nutr. 1993;14:211-218 Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus.
27. 2007 Nov-Dec;47(10):1436-43 Insulin metabolism is altered in migraineurs. Cavestro, C. et al
28. J Obstet Gynaecol 1990;97:847-52 vitamin B6 in the treatment of the premenstrual syndrome- a review, Kleijnen J. Riet GT et al
29. Int J]. Gunn AD Vitam Nutr Res. 1985;Suppl 27:213–24 review
30. J Int Med Res 1985;13:174-9 Controlled trial of B6 in PMS Harris RI, Deand BC
31. Lancet 1985;1399 B6 and PMS Brush MG, Perry M.
32. BMJ 1999;318;1375-81 Systematic Review B6 and PMS Dimmock PW et al
33. Arch Dermatol 1974;110:130-131 B6 for premenstrual acne Snider B et al
34. J Invest Dermatol 1942;5:143-8 B6 on resistant adolescent acne. Joliffe N et al
35. Clin Neuropharmacol 30(1):25-38 Electrical mapping of the effect of theanine. Higgin BA et al
36. Bio Psychol 74(1):39-45 Theanine reduces psychological and physiological stress Ozeki M et al.
37. Biol Psychol 77(2):113-22 Effects of theanine and caffeine on cognition and mood Kimura k et al.